FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165473671> ?p ?o ?g. }

• W3165473671 abstract "Background: The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-moderate disease are lacking. We assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-moderate COVID-19. Methods:  This open-label, randomised superiority clinical trial at 19 centres in the United Kingdom enrolled adults, ≥18 years, presenting to hospitals with clinically-diagnosed highly-probable or confirmed COVID-19 infection, with <14 days symptoms, considered suitable for initial ambulatory management. Patients were randomised (1:1) to azithromycin (500 mg daily orally for 14 days) or to standard care without macrolides. The primary outcome was the difference in proportion of participants with death or hospital admission from any cause over the 28 days from randomisation, assessed according to intention-to-treat (ITT). Trial registration: ClinicalTrials.gov, NCT04381962, Study closed. Findings: 298 participants were enrolled from 3 rd  June 2020 to 29 th  January 2021. The primary outcome was assessed in 292 participants. The primary endpoint was not significantly different between the azithromycin and control groups (Adjusted OR 0·91 [95% CI 0·43-1·92], p=0·80). Rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events, were not significantly different between groups. Interpretation: In patients with mild-moderate COVID-19 managed without hospital admission, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospitalisation or death. Our findings do not support the use of azithromycin in patients with mild-moderate COVID-19. Trial Registration: This trial was registered with ClinicalTrials.gov (NCT04381962) and EudraCT (2020-001740-26).Funding: NIHR Oxford BRC, University of Oxford and Pfizer Inc.Declaration of Interests: TSCH has received grants from Pfizer Inc., grants from University of Oxford, grants from the Wellcome Trust, grants from The Guardians of the Beit Fellowship, and grants from the NIHR Oxford Biomedical Research Centre during the conduct of the study; and personal fees from Astra Zeneca, personal fees from TEVA, personal fees from Peer Voice outside the submitted work. MJ has received grants from the University of Oxford and NIHR Oxford Biomedical Research Centre. DR has undertaken paid consultancy for GSK outside the submitted work. IDP reports personal fees from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, GlaxoSmithKline, Genentech, Regeneron, Teva, Chiesi, Sanofi, Circassia, Knopp, and grants from NIHR outside the submitted work. JU has received honoraria for preparation of educational materials and has served on an advisory board for Gilead Sciences and ViiV Healthcare outside of the submitted work. LC, RK, AW, JLC, VSB, JB, SJD, JM, PM, RG, TB, GJ, FC, DC, SE, DL and SM declare they have no competing interests.Ethics Approval Statement: The trial protocol was reviewed and approved by the UK Medicines and Healthcare products Regulatory Agency and an independent ethical committee (London – Brent Research Ethics Committee, Research Ethics Committee reference number 20/HRA/2105)." @default.
• W3165473671 created "2021-06-07" @default.
• W3165473671 creator A5004547714 @default.
• W3165473671 creator A5005315234 @default.
• W3165473671 creator A5005853376 @default.
• W3165473671 creator A5008169295 @default.
• W3165473671 creator A5009213464 @default.
• W3165473671 creator A5010728414 @default.
• W3165473671 creator A5011558684 @default.
• W3165473671 creator A5017736183 @default.
• W3165473671 creator A5023483978 @default.
• W3165473671 creator A5030020531 @default.
• W3165473671 creator A5034784907 @default.
• W3165473671 creator A5039795448 @default.
• W3165473671 creator A5052500107 @default.
• W3165473671 creator A5058578454 @default.
• W3165473671 creator A5061337574 @default.
• W3165473671 creator A5067920302 @default.
• W3165473671 creator A5069076021 @default.
• W3165473671 creator A5071108844 @default.
• W3165473671 creator A5075349431 @default.
• W3165473671 creator A5078489750 @default.
• W3165473671 creator A5084148999 @default.
• W3165473671 creator A5087425749 @default.
• W3165473671 date "2021-01-01" @default.
• W3165473671 modified "2023-10-16" @default.
• W3165473671 title "A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial" @default.
• W3165473671 doi "https://doi.org/10.2139/ssrn.3827019" @default.
• W3165473671 hasPublicationYear "2021" @default.
• W3165473671 type Work @default.
• W3165473671 sameAs 3165473671 @default.
• W3165473671 citedByCount "1" @default.
• W3165473671 countsByYear W31654736712021 @default.
• W3165473671 crossrefType "journal-article" @default.
• W3165473671 hasAuthorship W3165473671A5004547714 @default.
• W3165473671 hasAuthorship W3165473671A5005315234 @default.
• W3165473671 hasAuthorship W3165473671A5005853376 @default.
• W3165473671 hasAuthorship W3165473671A5008169295 @default.
• W3165473671 hasAuthorship W3165473671A5009213464 @default.
• W3165473671 hasAuthorship W3165473671A5010728414 @default.
• W3165473671 hasAuthorship W3165473671A5011558684 @default.
• W3165473671 hasAuthorship W3165473671A5017736183 @default.
• W3165473671 hasAuthorship W3165473671A5023483978 @default.
• W3165473671 hasAuthorship W3165473671A5030020531 @default.
• W3165473671 hasAuthorship W3165473671A5034784907 @default.
• W3165473671 hasAuthorship W3165473671A5039795448 @default.
• W3165473671 hasAuthorship W3165473671A5052500107 @default.
• W3165473671 hasAuthorship W3165473671A5058578454 @default.
• W3165473671 hasAuthorship W3165473671A5061337574 @default.
• W3165473671 hasAuthorship W3165473671A5067920302 @default.
• W3165473671 hasAuthorship W3165473671A5069076021 @default.
• W3165473671 hasAuthorship W3165473671A5071108844 @default.
• W3165473671 hasAuthorship W3165473671A5075349431 @default.
• W3165473671 hasAuthorship W3165473671A5078489750 @default.
• W3165473671 hasAuthorship W3165473671A5084148999 @default.
• W3165473671 hasAuthorship W3165473671A5087425749 @default.
• W3165473671 hasBestOaLocation W31654736712 @default.
• W3165473671 hasConcept C126322002 @default.
• W3165473671 hasConcept C2778907293 @default.
• W3165473671 hasConcept C2779134260 @default.
• W3165473671 hasConcept C2993769353 @default.
• W3165473671 hasConcept C3008058167 @default.
• W3165473671 hasConcept C35785553 @default.
• W3165473671 hasConcept C501593827 @default.
• W3165473671 hasConcept C524204448 @default.
• W3165473671 hasConcept C535046627 @default.
• W3165473671 hasConcept C71924100 @default.
• W3165473671 hasConcept C86803240 @default.
• W3165473671 hasConcept C89423630 @default.
• W3165473671 hasConceptScore W3165473671C126322002 @default.
• W3165473671 hasConceptScore W3165473671C2778907293 @default.
• W3165473671 hasConceptScore W3165473671C2779134260 @default.
• W3165473671 hasConceptScore W3165473671C2993769353 @default.
• W3165473671 hasConceptScore W3165473671C3008058167 @default.
• W3165473671 hasConceptScore W3165473671C35785553 @default.
• W3165473671 hasConceptScore W3165473671C501593827 @default.
• W3165473671 hasConceptScore W3165473671C524204448 @default.
• W3165473671 hasConceptScore W3165473671C535046627 @default.
• W3165473671 hasConceptScore W3165473671C71924100 @default.
• W3165473671 hasConceptScore W3165473671C86803240 @default.
• W3165473671 hasConceptScore W3165473671C89423630 @default.
• W3165473671 hasLocation W31654736711 @default.
• W3165473671 hasLocation W31654736712 @default.
• W3165473671 hasOpenAccess W3165473671 @default.
• W3165473671 hasPrimaryLocation W31654736711 @default.
• W3165473671 hasRelatedWork W2003594929 @default.
• W3165473671 hasRelatedWork W2026462764 @default.
• W3165473671 hasRelatedWork W2142722813 @default.
• W3165473671 hasRelatedWork W2312635070 @default.
• W3165473671 hasRelatedWork W2398428823 @default.
• W3165473671 hasRelatedWork W2766832809 @default.
• W3165473671 hasRelatedWork W2982038996 @default.
• W3165473671 hasRelatedWork W3000734051 @default.
• W3165473671 hasRelatedWork W3087455868 @default.
• W3165473671 hasRelatedWork W4292283255 @default.
• W3165473671 isParatext "false" @default.
• W3165473671 isRetracted "false" @default.
• W3165473671 magId "3165473671" @default.
• W3165473671 workType "article" @default.